Injectable drug delivery technology market Growth Analysis Report, Forecast to 2028
The increasing adoption of self-administrated drugs that require regular doses, favored by cost-effectiveness and reduced hospital visits is boosting sales in the market. In addition to this, the growing preference for smart devices that can track doses and facilitate patient compliance is expected to remain one of the chief drivers of the injectable drug delivery technology market over the assessment period.
The global Injectable Drug Delivery Market are slated to top US$ 41.5 Bn in 2022, projects Future Market Insights (FMI). Expanding at a healthy 8.9% CAGR, the market size is projected to total US$ 69.13 Bn by 2028.
2022-2028 Injectable Drug Delivery Market Outlook in Comparison to Growth Registered in 2014-2021
Demand for injectable drug delivery is poised to grow at a robust 8.9% CAGR, in comparison with the 7.2% CAGR registered between 2014 and 2021.
Burgeoning demand for cost-effective and quality drug injectors is encouraging product development in the market. The COVID-19 outbreak has spurred awareness regarding hygienic and safe injectors, which is compelling several manufacturers to launch sterile injectables, auto-injectors drug delivery devices, and wearables.
Injectable devices primarily find applications in the treatment of diabetes. As per the World Health Organization (WHO), diabetes incidence rose from 108 million in 1980 to 422 million in 2014. In 2019, diabetes was the ninth leading cause of death, with approximately 1.5 million deaths directly caused by the disease.
Diabetes patients are prescribed insulin which requires regular administration. On the flip side, the risk of needle-stick injuries is a common concern. Hence, injectable drug delivery and wearable insulin pumps are emerging as the most preferred options for diabetic patients. These devices have thin needles that eliminate the risk of injuries.
The introduction of smart wearables and devices that track time and dosage will continue boosting sales in the injectable drug delivery technology market. These devices send timely reminders and offer automatic dose adjustment to facilitate treatment adherence and compliance.
How is the Development of Novel Drugs Fast-tracking Growth in Injectable Drug Delivery Market?
Rinsing incidence of chronic ailments and other life-threatening diseases is underpinning the need for novel and effective drugs in various therapeutic areas. The convenience and at-home accessibility offered by injectable drugs are compelling manufacturers and pharmaceutical companies to develop efficient devices for the treatment of various ailments.
For instance, the use of injectable contraceptives has been increasing considerably since the last few years. This can be attributed to the high efficacy and convenience offered by these injectables. These contraceptives are not required to be taken daily, they can be administered once a month or three months. Due to this factor, sales of these injectable drug delivery devices are gaining traction.
Coupled with this, timely drug approvals by regulatory bodies such as the Food and Drug Administration (FDA) and the Medicines and Healthcare Products Regulatory Agency (MHRA) will widen the scope for the adoption of injectable drug delivery.

In January 2021, the FDA announced the approval of Cabenuva (cabotegravir and riprivine) in injectable formulation as a complete treatment regimen for human immunodeficiency virus type-1 (HIV-1) infection in adults. This is the first FDA-approved injectable which requires to be administered once a month.
Collaborations among pharmaceutical companions and research organizations for drug research and development are also expected to bode well for the market. In February 2021, for instance, Phillips Medisize and Subcuject announced a collaboration to launch a new wearable bolus injector.
Its simple osmotic drive offers low-cost bolus injection technology, allowing injectable wearable devices to be applied in a broader range of drugs. The new product meets the growing demand for large volume injectors to reduce injection frequency, and supports at-home medication delivery. Backed by such developments, the needle-free injectors market is expected to witness considerable growth in the forthcoming years. Country-wise Insights
How is the U.S. Injectable Drug Delivery Market Faring?
“Increasing Cases of Cancer to Boost the Development of Injectable Drug Delivery Devices”
The rising incidence of chronic diseases, such as cancer and diabetes in the U.S. is anticipated to spur the demand for smart and effective drug delivery options for better treatment. This is likely to usher new product developments by manufacturers and research institutes in the country, thereby boosting the growth. As per FMI, the North America market is projected to account for 33.4% of the total market share in 2021.
As per the National Cancer Institute, an estimated 1,806,590 new cases of cancer were diagnosed in the U.S. in 2020. This is expected to propel the development of novel injectable drug delivery devices in the oncology sector, thereby augmenting the growth of the U.S. market.
The presence of a robust healthcare sector, public healthcare reimbursements, and delivery of medical devices and medications through online channels will also continue to augment the U.S. market in the forthcoming years.
What is the U.K. Injectable Drug Delivery Market Outlook?
“Technological Development of Auto-injectors Drug Delivery to Propel the Growth”
Growing demand for smart and effective wearables for patient care in the U.K. is expected to boost sales over the assessment period. The Europe injectable drug delivery technology market is forecast to command 29.4% of the global market share in 2021, finds FMI.
Ongoing technological advancements in self-injection devices, especially in auto-injectors drug delivery and wearables for the administration of large volume and high-viscosity drugs are creating lucrative opportunities for market players in the U.K. This is expected to continue fueling the growth of the market.
Apart from that, the introduction of connective technology, such as Artificial Intelligence (AI) and Bluetooth in smart wearables is expected to bode well for the U.K. market. These devices send alerts regarding dosage timings and track dosages, thereby making them an effective drug delivery method for the elderly.
Why is the China Injectable Drug Delivery Market Witnessing High Demand?
“Availability of Low-cost Raw Materials to Push the Sales of Self-injection Devices”
China is expected to account for a dominant share in the East Asia market over the forecast period. As per FMI, East Asia is expected to account for 14.4% of the total market share in 2021.
Increasing investments in the expansion of the healthcare sector by government bodies in China are creating a conducive environment for novel drug development in the country. Various global pharmaceutical companies are aiming to expand their footprints in China, owing to the wide availability of low-cost raw materials and growing demand for branded drugs, as well as self-injection devices.
Further, the expansion of the biologics sector will continue pushing sales in the market. Increasing production of vaccines, insulin, gene and cellular therapies, growth inhibitors, and cytokines in the biologics sector is spurring the demand for effective drug delivery options, which in turn, is augmenting the growth of the market in China. Competition Landscape
Leading players operating in the global injectable drug delivery technology market are focusing on research and development activities to launch innovative products in the market. In addition to this, these players are investing in mergers, acquisitions, and collaborations to gain a competitive edge in the injectable drug delivery technology market.
For instance: In September 2021, Antares Pharma, Inc. announced that it has begun the phase 1 study for ATRS-1902 for adrenal crisis rescue. The program supports a proposed indication for treatment of acute adrenal insufficiency in adults and adolescents, using a new proprietary auto-injector platform to deliver a liquid formulation of hydrocortisone.
In November 2021, Becton, Dickinson and Company launched the BD Ultrasafe Plus 2.25 ml Passive Needle Guard for use in drug-device combination products. When combined with Glass Prefillable Syringe, the new system enables delivery of biologic solutions of different volumes up to 2ml and viscosities of up to 30 cP.
Click here For More Info: https://www.futuremarketinsights.com/reports/injectable-drug-delivery-market